Based on the outstanding expertise and rich experience, Creative Biolabs has specially developed a system approach of TCR generation and optimization for TCR development. The phage surface display is an effective technology optimized by our expert team, which will be signally promote the ability of recognition to tumor antigen.
T cells expressing antigen-specific TCRs mediate the elimination of tumor and virally infected cells by recognition of antigen in the form of individual peptides bound to MHC molecules. Although interactions between TCR and the restriction MHC element have been detected only in the presence of specific peptides, it is believed that this thymic-positive selection imposes a low self-MHC affinity onto the peripheral T cell pool. Several creative approaches have been used to generate TCRs that are specific for other antigens expressed by a wider variety of tumor cell types.
In order not to generate T cell clones depending on the ability, yet allowing for the selection of high-affinity TCRs that are reactive against a variety of antigens, Creative Biolabs has developed a remarkable method that does not require patient material to obtain a tumor-antigen-reactive. TCR is use of phage display technology for TCR isolation. This approach, which bypasses the need for a T-cell clone, may be generically suitable for isolation of antigen-specific TCRs from polyclonal T-cell populations.
Creative Biolabs has the capability to enable you to free up your time for core work and project. Our service can be designed to meet your special needs if you have any requirements. If you are interested in our service, please contact us by E-mail and our team will get back to you as soon as possible.
Tristen S. Park, et al. Treating cancer with genetically engineered T cells. Trends in Biotechnology, 2011, 29 (11): 550-557.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE